Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo

Anti-CD19 chimeric antigen receptor (CAR) T-cells are an effective treatment for refractory B-cell lymphoma, but CD19 deletion is prone to relapse. We conducted this study to find more effective dual CAR19/20 T-cells to target B-cell lymphoma and prevent antigen loss leading to recurrence. In this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Yuzhen, Zhang, Pengchao, He, Ling, Guo, Xianling, Wang, Hui, Li, Jun, Xu, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410781/
https://www.ncbi.nlm.nih.gov/pubmed/36034960
http://dx.doi.org/10.1155/2022/1227308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410781/
https://www.ncbi.nlm.nih.gov/pubmed/36034960
http://dx.doi.org/10.1155/2022/1227308

Ejemplares similares